Hemolytic potential of structurally related aniline halogenated hydroxylamines

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 24, Issue 1, 2005, Pages 67-76

  Singh, Harpal ^a   Purnell, Elissa T ^a  

^a SAVANNAH STATE UNIVERSITY   (United States)

Author keywords

Aniline metabolites; Erythrocytes; Halogenated phenylhydroxylamines; Hemolysis; Hemolytic anemia; Red blood cells

Indexed keywords

4 BROMOPHENYLHYDROXYLAMINE; 4 FLUOROPHENYLHYDROXYLAMINE; 4 IODOPHENYLHYDROXYLAMINE; ANILINE; CHROMIUM 51; HALIDE; HYDROXYLAMINE; UNCLASSIFIED DRUG; ANILINE DERIVATIVE; HALOGENATED HYDROCARBON;

ANIMAL CELL; ARTICLE; CELL DESTRUCTION; CELL LOSS; CONTROLLED STUDY; DOSE RESPONSE; ELECTRON; ERYTHROCYTE; HEMOLYSIS; HEMOLYTIC ANEMIA; ISOTOPE LABELING; MALE; METABOLITE; MOLECULAR STABILITY; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RAT; STRUCTURE ACTIVITY RELATION; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; DRUG STABILITY; OXIDATION REDUCTION REACTION; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALIA;

ANEMIA, HEMOLYTIC; ANILINE COMPOUNDS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG STABILITY; ERYTHROCYTES; HEMOLYSIS; HYDROCARBONS, HALOGENATED; HYDROXYLAMINES; MALE; OXIDATION-REDUCTION; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 15044350017     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/JEnvPathToxOncol.v24.i1.70     Document Type: Article

References (41)

1. Cleaves RL. Antipyretics in continued fevers. Iowa State Med Soc 1892; 10:84-89.
2. West FE. Notes on the therapeutics of certain antipyretics. Brooklyn Med J 1893; 7:325-365.
3. Beutler E. Drug-induced hemolytic anemia. Pharmacol Rev 1969; 21:73-103.
4. Tarlov AR, Brewer GJ, Carson PE, Alving AS. Primaquine sensitivity. Arch Intern Med 1962; 109:137-162.
5. Carson PE. Glucose-6-phosphate dehydrogenase deficiency and related disorders of the phosphate pathway. Am J Medicine 1966; 41:744-761.
6. Raupp P, Hassan JA, Varughese M, Kristiansson B. Henna causes life threatening haemolysis in glucose-6-phosphate dehydrogenase deficiency. Arch Dis Child 2001, 85:411-412.
7. Jollow DJ, McMillan DC. Oxidative stress, glucose-6-phosphate dehydrogenase and the red cell. Adv Exp Med Bio 2001; 500:595-605.
8. Grossman SJ, Jollow DJ. Role of dapsone hydroxylamines in dapsone-induced hemolytic anemia. J Pharmacol Exp Ther 1988; 244:118-125
9. Reider MJ, Uetrecht J, Shear NH, Spielberg SP. Synthesis and in vitro toxicity if hydroxylamine metabolites of sulfonamides. J Phamacol Exp Ther 1988; 244:724-728.
10. Coleman MD, Breckenridge AM, Park BK. Bioactivation of dapsone to a cytotoxic metabolite by human hepatic microsomal enzymes. Br J Clin Pharmacol 1989; 28:389-395.
11. Cribb AE, Miller M, Leeder JS, Hill J, Spielberg SP. Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Implications for idiosyncratic toxicity. Drug Metab Dispos 1991; 19:900-906.
12. Jollow DJ, Bradshaw TP, McMillan DC. Dapsone-induced hemolytic anemia. Drug Metab Rev 1995; 27:107-124.
13. Bolchoz LJC, Budinsky RA, McMillan DC, Jollow DJ. Primaquine-induced hemolytic anemia: formation and hemotoxicity of the arylhydroxylamine metabolite 6-methoxy-8-hydroxylaminoquinoline. J Pharmacol Exp Ther 2001; 297:509-515.
14. Jensen CB, Jollow DJ. The role of N-hydroxyphenetidine in phenacetin-induced hemolytic anemia. Toxicol Appl Pharmacol 1991; 111:1-12.
15. McMillan DC, Bradshaw TP, Hinson JA, Jollow DJ. Role of metabolites in propanil-induced hemolytic anemia. Toxicol Appl Pharmacol 1991; 110:70-78.
16. Grossman SJ, Simson J, Jollow DJ. Dapsone-induced hemolytic anemia: Effect of N-hydroxy dapsone on the sulfhydryl status and membrane proteins of rat erythrocytes. Toxicol Appl Pharmacol 1992; 117:208-217.
17. McMillan DC, Simson JV, Budinsky RA, Jollow DJ. Dapsone-induced hemolytic anemia: effect of dapsone hydroxylamine on sulfhydryl status, membrane skeletal proteins and morphology of human and rat erythrocytes. J Pharmacol Exp Ther 1995; 274:540-547.
18. Bolchoz LJC, Morrow JD, Jollow DJ, McMillan DC. Primaquine-induced hemolytic anemia: effect of 6-methoxy-8-hydroxylaminoquinoline on rat erythrocyte sulfydrayl status, membrane lipids, cytoskeletal proteins and morphology. J Pharmacol Exper Ther 2002; 303:141-148.
19. Bowmann ZS, Oatis JE, Whelan JE, Jollow DJ, McMillan DC. Primaquine-induced hemolytic anemia: susceptibility of normal vs. glutathione-depleted rat erythrocytes to 5-hydroxylprimaquine. J Pharmacol Exp Ther 2004; 309:79-85.
20. McMillan DC, Bolchoz LJ, Jollow Dj. Favism: effect of divicine on rat erythrocyte sulfydryl status, hexose monophosphate shunt activity, morphology and membrane skeletal proteins. 2001; 62:353-359.
21. Kiese M. The biomedical production of ferrihemoglobin-forming derivatives from aromatic amines and mechanisms of ferrihemoglobin formation. Pharmacol Rev 1966; 18:1091-1161.
22. Cohen G, Hochstein P. Generation of hydrogen peroxide in erythrocytes by hemolytic agents. Biochemistry 1964; 3:895-900.
23. Carrell RW, Winterbourn CC, Rachmilewitz EA. Activated oxygen and hemolysis. Br J Haematol 1975; 30: 259-264.
24. Misra HP, Fridovich I. The oxidation of phenylhydrazine: superoxide and mechanism. Biochemistry 1976; 15:681-687.
25. Itano HA, Hirota K, Vedvick TS. Ligands and oxidants in ferrihemochrome formation and oxidative hemolysis. Proc Natl Acad Sci USA 1977; 74:2556-2560.
26. Goldberg B, Stern A. The mechanism of oxidative hemolysis produced by phenylhydrazine. Mol Pharmacol 1977; 13:832-839.
27. Harrison JH Jr, Jollow DJ. Role of aniline metabolites in aniline-induced hemolytic anemia. J Pharmacol Exp Ther 1986; 238:1045-1054.
28. Valentovic MA, Rogers BA, Meadows MK, Conner JT, Williams E, Hong SK, Rnakin GO. Characterization of methemoglobin formation induced by 3,5-dichloroaniline, 4-amino-2,6-dichlorophenol and 3,5 - dichlorophenylhydroxylamine. Toxicology 1997; 118:23-26.
29. Coleman MD, Tingle MD, Hussain F, Storr RC, Park BK. An investigation into the haematological toxicity of structural analogues of dapsone in-vivo and in-vitro. J Pharm Pharmacol 1991; 43:779-7784.
30. McMillan David C, Sarvate Snehal D, Oatis John E, Jollow David J. Role of oxidant stress in Lawsone-induced hemolytic anemia. Toxicol Sci 2004; 82:647-655.
31. Vage C, Saab N, Woster PM, Svensson CK. Dapsone-induced hematologic toxicity: Comparison of the methemoglobin-forming ability of hydroxylamine metabolites of dapsone in rat and human blood. Toxicol Appl Pharmacol 1994; 129:309-316.
32. French CL, Yaun SS, Baldwin LA, Leonard DA, Zhao XQ, Calabrese EJ. Potency ranking of methemoglobin-forming agents. J Appl Toxicol 1995; 15:167-174.
33. Ward KE, McCarthy MW. Dapsone-induced methemoglobin. Ann Pharmacother 1998; 32:549-553.
34. Reilly TP, Woster PM, Svensson CK. Methemoglobin formation by hydroxylamine metabolites of sulfamethoxazole and dapsone: implications for differences in adverse drug reactions. J Pharmacol Exp Ther 1999; 288:951-959.
35. Pauluhn P. Aniline-induced methemoglobinemia in dogs: pitfalls or route-to-route extrapolations. Inhal Toxicol 2002; 14:959-973.
36. Rockwood GA, Armstrong KR, Baskin SI. Species comparison of methemoglobin reductase. Exp Biol Med 2002; 228:79-83.
37. Eyer P. Reactions of nitrosobenzene with reduced glutathione. Chem Biol Interact 1979; 24:227-239.
38. Murayama M. The combining power of normal human hemoglobin for nitrosobenzene. J Biol Chem 1960; 235:1024-1028.
39. Kiese M, Traeger K. The fate of phenylhydroxylamine in human red cells. Naunyn-Schmiedeberg's Arch Pharmacol 1976; 292:59-66.
40. Wright MS. Drug-induced hemolytic anemias: increasing complications to therapeutic interventions. Clin Lab Sci 1999; 12:115-118
41. Grossman S, Budinsky RA, Jollow DJ. Dapsone-induced hemolytic anemia: role of glucose-6-phosphate dehydrogenase in the hemolytic response of rat erythrocytes to N-hydroxydapsone. J Pharmacol Exp Ther 1995; 273:870-877.